Notification of Drug Policy Revisions Effective January 1, 2023 (Posted October 17, 2022)

Policy Name	Revised Criteria
Infliximab (Remicade®) and Infliximab Biosimilars	Changed requirement for trial and failure of preferred agents to include two agents: Avsola and Inflectra. Adjusted non-preferred agents to include Remicade and Infliximab. Policy notification given 10/17/2022 for effective date 1/1/2023.

Policy Name

Revised Criteria

Infliximab (Remicade®) and Infliximab Biosimilars

Changed requirement for trial and failure of preferred agents to include two agents: Avsola and Inflectra. Adjusted non-preferred agents to include Remicade and Infliximab. Policy notification given 10/17/2022 for effective date 1/1/2023.

Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.

Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語

© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.